Jones, Samuel E. http://orcid.org/0000-0003-0153-922X
van Hees, Vincent T. http://orcid.org/0000-0003-0182-9008
Mazzotti, Diego R.
Marques-Vidal, Pedro http://orcid.org/0000-0002-4548-8500
Sabia, Séverine
van der Spek, Ashley
Dashti, Hassan S. http://orcid.org/0000-0002-1650-679X
Engmann, Jorgen
Kocevska, Desana
Tyrrell, Jessica http://orcid.org/0000-0002-9256-6065
Beaumont, Robin N. http://orcid.org/0000-0003-0750-8248
Hillsdon, Melvyn
Ruth, Katherine S. http://orcid.org/0000-0003-4966-9170
Tuke, Marcus A. http://orcid.org/0000-0003-0008-9263
Yaghootkar, Hanieh
Sharp, Seth A.
Ji, Yingjie
Harrison, Jamie W. http://orcid.org/0000-0002-8314-9411
Freathy, Rachel M. http://orcid.org/0000-0003-4152-2238
Murray, Anna
Luik, Annemarie I.
Amin, Najaf
Lane, Jacqueline M.
Saxena, Richa
Rutter, Martin K.
Tiemeier, Henning
Kutalik, Zoltán http://orcid.org/0000-0001-8285-7523
Kumari, Meena
Frayling, Timothy M.
Weedon, Michael N.
Gehrman, Philip R.
Wood, Andrew R.
Article History
Received: 11 September 2018
Accepted: 14 March 2019
First Online: 5 April 2019
Competing interests
: M.K.R reports receiving research funding from Novo Nordisk, consultancy fees from Novo Nordisk and Roche Diabetes Care, and modest owning of shares in GlaxoSmithKline. P.G. receives grant support from Merck, Inc. The other authors declare no competing interests.